Gilead staying conservative in HCV? Or changing its tune?
As expected, Gilead Sciences Inc. reported robust revenues for the fourth quarter of 2013, up 21 percent to $3.12 billion from $2.59 billion for the same period a year earlier. Total revenues for the full year were $11.2 billion, up 15 percent compared to $9.7 billion a year earlier, on record product sales of $10.8 billion – a 15 percent year-over-year increase.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST